Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis.
Fiche publication
Date publication
mai 2016
Journal
Arteriosclerosis, thrombosis, and vascular biology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOULAGNON-ROMBI Camille
Tous les auteurs :
Belmokhtar K, Robert T, Ortillon J, Braconnier A, Vuiblet V, Boulagnon-Rombi C, Diebold MD, Pietrement C, Schmidt AM, Rieu P, Touré F
Lien Pubmed
Résumé
Cardiovascular disease is the leading cause of death in patients with end-stage renal disease. Serum amyloid A (SAA) is an acute phase protein and a binding partner for the multiligand receptor for advanced glycation end products (RAGE). We investigated the role of the interaction between SAA and RAGE in uremia-related atherogenesis.
Référence
Arterioscler. Thromb. Vasc. Biol.. 2016 May;36(5):800-9